These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36639195)

  • 1. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
    Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
    Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
    Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
    Zou RY; Yuan L; Chen M; Yao LQ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique.
    Macciò A; Sanna E; Lavra F; Chiappe G; Petrillo M; Madeddu C
    BMC Surg; 2021 Oct; 21(1):380. PubMed ID: 34711237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer.
    Finch L; Chi DS
    J Gynecol Oncol; 2023 Sep; 34(5):e84. PubMed ID: 37545363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
    Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
    J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.
    Zou R; Jiang Q; Luo X; Chen M; Yuan L; Yao L
    World J Surg Oncol; 2023 Nov; 21(1):375. PubMed ID: 38037085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
    Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.